In conclusion, PHI-101, a selective Chk2 inhibitor, is a promising molecule to overcome the current treatment for platinum-resistant recurrent ovarian cancer, and it is necessary to conduct a study to assess the safety and tolerability of PHI-101. This evidence concerns the gene CHEK2 and ovarian carcinoma.